1. Mareev, V.Yu., Ageev, F.T., Arutyunov, G.P., Koroteev, A.V., and Revishvili, A.Sh., National recommendations of the VNOK and OSSN for the diagnosis and treatment of CHF (third revision), J. Heart Failure, 2009, vol. 10, no. 2, pp. 64–106.
2. Bazzino, O., Furreni, J.J., Botto, F., De Arenaza, D.P., Bahit, C., and Dadone, J., Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes, Eur. Heart J., 2004, vol. 25, no. 10, pp. 859–866. https://doi.org/10.1016/j.ehj.2004.03.004
3. Schrader, E.V., Shakhnovich, R.M., Kaznachee-va, E.I., Bosykh, E.G., Tkachev, G.A., and Ore, M.Ya., Prognostic value of markers of inflammation and NT-pro-BNP in various treatment options for patients with acute coronary syndrome, Cardiol. Bull., 2008, vol. 3, no. 2, pp. 44–53.
4. Makoeva, M.H., Fedorova, M.M., Avtandilov, A.G., Semitko, S.P., Dolgov, V.V., and Roitman, A.P., Dynamics and prognostic value of cerebral natriuretic peptide and C-reactive protein in acute myocardial infarction depending on treatment tactics, Klin. Lab. D-iagn., 2014, vol. 59, no. 2, pp. 23–26.
5. Conssens, L.M. and Werb, Z., Inflammatory cells and cancer: Think different, J. Exp. Med., 2001, vol. 193, pp. 23–26. https://doi.org/10.1084/jem.193.6.f23